NexImmune (NEXI) has released an update to notify the public and investors about a termination of a material definitive agreement.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NexImmune, Inc. had an agreement with Cantor Fitzgerald & Co. and BTIG, LLC to sell shares of common stock through an “at the market” program, aiming to raise up to $50 million. They terminated the agreement on February 2, 2024, without incurring material penalties. Before termination, NexImmune sold 127,396 shares, netting approximately $5.1 million.
For further insights into NEXI stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.